| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 380.40 | 31.1% |
| Total Income | 381.40 | 31.0% |
| Expenditure | 411.80 | 15.0% |
| PBT | -30.40 | 144.5% |
| Net Profit | -22.40 | 144.6% |
| OPM | 6.60% | 15.74pp |
| NPM | -5.87% | 14.95pp |
| EPS | 1.82 | 55.3% |
Hikal Ltd. Reports Q1 FY26 Earnings: Revenue at Rs 380 Crore, EBITDA at Rs 25 Crore
07 Aug 2025 · 7 Aug 2025, 03:51 pm
Summary
Hikal Ltd., a preferred long-term partner for leading global life sciences companies, announced its unaudited financial results for the quarter ended 30th June 2025. The company's consolidated revenue stood at Rs. 380 Crore, with EBITDA at Rs. 25 Crore. The pharmaceuticals segment delivered revenue of Rs. 203 Cr, with an EBIT margin of -12.9%. The crop protection business reported revenue of Rs. 178 Cr with an EBIT margin of 9.7%. Despite the challenging start to the year, the company remains confident of delivering on its guidance for FY26.
Key Highlights
- 1
Revenue recorded at Rs 380 Crore, impacted by deferred offtake post USFDA OAI in May 2025
- 2
Regulatory audits of Bangalore facilities by ANVISA, Brazil and PMDA, Japan concluded successfully
- 3
Progress in the Personal Care and Specialty Chemicals space
- 4
Focus on cost optimization, operational efficiency, and compliance culture
- 5
Strengthening the balance sheet with improvement in operating cashflow and reduction in debt
- 6
Pharmaceuticals revenue declined due to short-term pause in customer offtake post-OAI status
- 7
Volumes in key products and markets impacted during the quarter; margin mix remains unfavorable
- 8
Expanding capabilities to support high-potency and complex chemistry projects
- 9
Developing differentiated products for enhancing own product portfolio
- 10
Registrations continue to come through in regulated markets such as EU, Japan and Australia
- 11
Revenue for the quarter remains flat for Crop-Protection
- 12
Margins remain under pressure in Crop-Protection
- 13
Crop Protection industry undergoing strategic realignments leading to near term challenges and long term opportunities
Management Comments
Jai Hiremath
Executive Chairman, Hikal Ltd.
The global chemical and life sciences industry continues to face mitigated headwinds, marked by a gradual pickup in demand and capacity utilization, though pricing remains under pressure in some segments. Escalating tariff uncertainties and ongoing trade realignments have added a layer of volatility to global supply chains and procurement cycles. For Q1 FY26, our consolidated revenue stood at Rs. 380 Cr, with EBITDA at Rs. 25 Cr, reflecting a lower-than-forecasted start to the financial year. Our pharmaceutical segment delivered revenue of Rs. 203 Cr, with an EBIT margin of -12.9%...Despite the challenging start to the year in Q1 we remain confident of delivering on our guidance for FY26. We expect a more meaningful recovery in Q3 and Q4 FY26, supported by increased demand visibility, improved capacity utilization, and new product commercialization.
Informational and educational content only. Not investment advice.